Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Kiniksa Pharmaceuticals Q2 2024 GAAP EPS $(0.06), Inline, Sales $108.631M Beat $92.313M Estimate

Author: Benzinga Newsdesk | July 23, 2024 07:31am

Posted In: KNSA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist